Open AccessPhase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck
Author(s) -
Dong M. Shin,
Sreenivas Nannapaneni,
Mihir R. Patel,
Qiuying Shi,
Yuan Liu,
Zhengjia Chen,
Amy Chen,
Mark W. ElDeiry,
Jonathan J. Beitler,
Conor E. Steuer,
Steven M. Roser,
Adam M. Klein,
Taofeek K. Owonikoko,
Suresh S. Ramalingam,
Fadlo R. Khuri,
Zhuo G. Chen,
Nabil F. Saba
Publication year - 2020
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-20-2276
Subject(s) - erlotinib , medicine , rash , toxicity , erlotinib hydrochloride , gastroenterology , oncology , cancer , epidermal growth factor receptor
On the basis of synergistic effects between green tea polyphenon E (PPE) and EGFR-tyrosine kinase inhibitor in preclinical studies, we conducted a phase Ib study of the PPE and erlotinib combination in patients with advanced premalignant lesions (APL) of the oral cavity and larynx.